Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Jacob Laubach
Dana-Farber Cancer Institute
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Colorado Blood Cancer Institute
Denver, Colorado, United States
- Eastern Maine Medical Center
Brewer, Maine, United States
- Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
- Dana Farber Cancer Institute
Boston, Massachusetts, United States
- Massachusetts General Hosptial
Boston, Massachusetts, United States
- Virginia Piper Cancer Institute
Coon Rapids, Minnesota, United States
- Virgina Piper Cancer Institute
Minneapolis, Minnesota, United States
- Hematology Oncology of Northern New Jersey
Morristown, New Jersey, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Dec 2015
- Primary completion
- 31 Dec 2021
- Completion
- 31 Oct 2025
- Last update posted
- 13 Jan 2026
- Registered enrollment
- 46
- Registry id
- NCT02441686
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.